Sponsors / SLS
SLS

Sellas Life Sciences Group

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
3Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapyNCT01265433Sellas Life Sciences GroupPhase 2Completed2016-11-30Actual
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)NCT01266083Sellas Life Sciences GroupPhase 2Completed2016-09-30Actual
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979Sellas Life Sciences GroupPhase 3Active not recruiting2025-12Estimated

Latest recorded trial changes